Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
- Safety and tolerability of three regimens of intravesically administered BC-819/PEI and
BCG (number of participants with AEs, discontinuations due to AEs)
- Recurrence after treatment with BC-819/PEI and BCG
- Approximately 38 patients with superficial transitional cell carcinoma TCC) of the
bladder
- After initial evaluation and qualification, patients will be randomized to one of three
treatment groups, either alternating, sequential or twice weekly